Bhargava A, Popel A, Pathak A
Microvasc Res. 2023; 149:104555.
PMID: 37257688
PMC: 10526652.
DOI: 10.1016/j.mvr.2023.104555.
Foda A, Kellner E, Gunawardana A, Gao X, Janz M, Kufner A
Clin Neuroradiol. 2021; 32(1):239-248.
PMID: 34940899
PMC: 8894153.
DOI: 10.1007/s00062-021-01129-8.
Grist S, Nasseri S, Laplatine L, Schmok J, Yao D, Hua J
Sci Rep. 2019; 9(1):17782.
PMID: 31780697
PMC: 6883080.
DOI: 10.1038/s41598-019-54001-8.
Zheng X, Cui L, Chen M, Soto L, Graves E, Rao J
Cancer Res. 2019; 79(18):4787-4797.
PMID: 31311808
PMC: 6744984.
DOI: 10.1158/0008-5472.CAN-19-0530.
Forster J, Harriss-Phillips W, Douglass M, Bezak E
Hypoxia (Auckl). 2017; 5:21-32.
PMID: 28443291
PMC: 5395278.
DOI: 10.2147/HP.S133231.
The effect of tumour size on drug transport and uptake in 3-D tumour models reconstructed from magnetic resonance images.
Zhan W, Gedroyc W, Xu X
PLoS One. 2017; 12(2):e0172276.
PMID: 28212385
PMC: 5315397.
DOI: 10.1371/journal.pone.0172276.
The role of necrosis, acute hypoxia and chronic hypoxia in F-FMISO PET image contrast: a computational modelling study.
Warren D, Partridge M
Phys Med Biol. 2016; 61(24):8596-8624.
PMID: 27880734
PMC: 5717515.
DOI: 10.1088/1361-6560/61/24/8596.
Bioengineering strategies for designing targeted cancer therapies.
Alexander-Bryant A, Vanden Berg-Foels W, Wen X
Adv Cancer Res. 2013; 118:1-59.
PMID: 23768509
PMC: 4165503.
DOI: 10.1016/B978-0-12-407173-5.00002-9.
A mathematical model for thermosensitive liposomal delivery of Doxorubicin to solid tumour.
Zhan W, Xu X
J Drug Deliv. 2013; 2013:172529.
PMID: 23401781
PMC: 3562666.
DOI: 10.1155/2013/172529.
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.
Dong X, Mumper R
Nanomedicine (Lond). 2010; 5(4):597-615.
PMID: 20528455
PMC: 2925023.
DOI: 10.2217/nnm.10.35.
Biological barriers to therapy with antisense and siRNA oligonucleotides.
Juliano R, Bauman J, Kang H, Ming X
Mol Pharm. 2009; 6(3):686-95.
PMID: 19397332
PMC: 2758224.
DOI: 10.1021/mp900093r.
Drug delivery and transport to solid tumors.
Jang S, Wientjes M, Lu D, Au J
Pharm Res. 2003; 20(9):1337-50.
PMID: 14567626
DOI: 10.1023/a:1025785505977.
Causes and effects of heterogeneous perfusion in tumors.
Gillies R, Schornack P, Secomb T, Raghunand N
Neoplasia. 2000; 1(3):197-207.
PMID: 10935474
PMC: 1508079.
DOI: 10.1038/sj.neo.7900037.
Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Teicher B, Holden S, Dupuis N, Kakeji Y, Ikebe M, Emi Y
Breast Cancer Res Treat. 1995; 36(2):227-36.
PMID: 8534870
DOI: 10.1007/BF00666043.
beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher B, Sotomayor E, Huang Z, Ara G, Holden S, Khandekar V
Cancer Chemother Pharmacol. 1993; 33(3):229-38.
PMID: 8269604
DOI: 10.1007/BF00686221.
Characterisation of tumour blood flow using a 'tissue-isolated' preparation.
Tozer G, Shaffi K, Prise V, Cunningham V
Br J Cancer. 1994; 70(6):1040-6.
PMID: 7981052
PMC: 2033701.
DOI: 10.1038/bjc.1994.445.
Geographical mapping of metabolites in biological tissue with quantitative bioluminescence and single photon imaging.
Mueller-Klieser W, Walenta S
Histochem J. 1993; 25(6):407-20.
PMID: 7689547
DOI: 10.1007/BF00157805.
Clinical requirements for localized hyperthermia in the patient.
Thrall D
Radiat Environ Biophys. 1980; 17(3):229-32.
PMID: 7443978
DOI: 10.1007/BF01323649.
Endothelial-cell proliferation in experimental tumours.
Denekamp J, Hobson B
Br J Cancer. 1982; 46(5):711-20.
PMID: 7171453
PMC: 2011157.
DOI: 10.1038/bjc.1982.263.
Buoyant density of EMT6 fibrosarcoma cells: time course of the density changes after growth in hypoxia.
Ng C, Koch C, Inch W
Cell Biophys. 1980; 2(2):153-63.
PMID: 6159089
DOI: 10.1007/BF02795841.
